These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12172338)

  • 1. Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials.
    Stahl SM; Mendels J; Schwartz GE
    J Clin Psychopharmacol; 2002 Aug; 22(4):388-92. PubMed ID: 12172338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression.
    Ferguson JM; Mendels J; Schwart GE
    Int Clin Psychopharmacol; 2002 Mar; 17(2):45-51. PubMed ID: 11890185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case series on the use of lavendula oil capsules in patients suffering from major depressive disorder and symptoms of psychomotor agitation, insomnia and anxiety.
    Fißler M; Quante A
    Complement Ther Med; 2014 Feb; 22(1):63-9. PubMed ID: 24559818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of anxiety and agitation symptoms during nefazodone treatment of major depression.
    Fawcett J; Marcus RN; Anton SF; O'Brien K; Schwiderski U
    J Clin Psychiatry; 1995; 56 Suppl 6():37-42. PubMed ID: 7649972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antidepressant efficacy of reboxetine in patients with severe depression.
    Montgomery S; Ferguson JM; Schwartz GE
    J Clin Psychopharmacol; 2003 Feb; 23(1):45-50. PubMed ID: 12544375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
    Andreoli V; Caillard V; Deo RS; Rybakowski JK; Versiani M
    J Clin Psychopharmacol; 2002 Aug; 22(4):393-9. PubMed ID: 12172339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
    Fava M; McGrath PJ; Sheu WP;
    J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder.
    Versiani M; Amin M; Chouinard G
    J Clin Psychopharmacol; 2000 Feb; 20(1):28-34. PubMed ID: 10653205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial.
    Katona C; Bercoff E; Chiu E; Tack P; Versiani M; Woelk H
    J Affect Disord; 1999 Oct; 55(2-3):203-13. PubMed ID: 10628889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reboxetine in the maintenance therapy of depressive disorder in the elderly: a long-term open study.
    Aguglia E
    Int J Geriatr Psychiatry; 2000 Sep; 15(9):784-93. PubMed ID: 10984724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety.
    Fawcett J; Barkin RL
    J Clin Psychiatry; 1998 Mar; 59(3):123-7. PubMed ID: 9541155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study.
    Grassi L; Biancosino B; Marmai L; Righi R
    J Clin Psychiatry; 2004 Apr; 65(4):515-20. PubMed ID: 15119914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
    Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S
    Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reboxetine: tolerability and safety profile in patients with major depression.
    Tanum L
    Acta Psychiatr Scand Suppl; 2000; 402():37-40. PubMed ID: 10901157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine.
    Nelson JC; Portera L; Leon AC
    J Clin Psychiatry; 2005 Nov; 66(11):1409-14. PubMed ID: 16420078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reboxetine in the treatment of depression in the elderly: pilot study.
    Andreoli V; Carbognin G; Abati A; Vantini G
    J Geriatr Psychiatry Neurol; 1999; 12(4):206-10. PubMed ID: 10616869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.
    Versiani M; Mehilane L; Gaszner P; Arnaud-Castiglioni R
    J Clin Psychiatry; 1999 Jun; 60(6):400-6. PubMed ID: 10401920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder.
    Versiani M; Cassano G; Perugi G; Benedetti A; Mastalli L; Nardi A; Savino M
    J Clin Psychiatry; 2002 Jan; 63(1):31-7. PubMed ID: 11838623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
    Langworth S; Bodlund O; Agren H
    J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder.
    Carvalhal AS; de Abreu PB; Spode A; Correa J; Kapczinski F
    J Clin Psychiatry; 2003 Apr; 64(4):421-4. PubMed ID: 12716244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.